Artelo Biosciences Executes Reverse Split to Boost Share Price and Liquidity
ARTL is trading near its 52-week low of $0.66 (4.5% above the low) on light trading volume (0.3× avg).
Summary
Artelo Biosciences is effecting a 1-for-9 reverse stock split effective Aug. 28, 2026, to raise its per-share price and improve marketability and liquidity. The split reduces outstanding shares from 4,929,966 to about 547,774 and authorized shares from 500 million to 55,555,556, with trading on a split-adjusted basis beginning Aug. 31. The company trades near its 52-week low at $0.69, and the split follows shareholder approval in July of a 3x increase in authorized shares and a highly dilutive financing agreement with Square Gate Capital. The reverse split is a mechanical step to maintain Nasdaq listing compliance and attract institutional interest, but it does not change the company's underlying fundamentals or cash position. With only $4.2 million in cash and going concern doubts reiterated in the latest 10-Q, the split may be a precursor to further capital raises.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 1-for-9 reverse split is effective Aug. 28, 2026, reducing outstanding shares from 4,929,966 to about 547,774 and authorized shares from 500 million to 55,555,556. Trading on a split-adjusted basis begins Aug. 31.
At the time of this announcement, ARTL was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.66 to $28.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.